Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018’, provides an overview of the Hypertrophic Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy

- The report reviews pipeline therapeutics for Hypertrophic Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hypertrophic Cardiomyopathy therapeutics and enlists all their major and minor projects

- The report assesses Hypertrophic Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypertrophic Cardiomyopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

C&C BioPharma LLC

Lead Discovery Center GmbH

MyoKardia Inc

C&C BioPharma LLC

Lead Discovery Center GmbH

MyoKardia Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypertrophic Cardiomyopathy – Overview

Hypertrophic Cardiomyopathy – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypertrophic Cardiomyopathy – Overview

Hypertrophic Cardiomyopathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hypertrophic Cardiomyopathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypertrophic Cardiomyopathy – Companies Involved in Therapeutics Development

C&C BioPharma LLC

Lead Discovery Center GmbH

MyoKardia Inc

Hypertrophic Cardiomyopathy – Drug Profiles

8-MI – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCM-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUS-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavacamten – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Agonize MFN2 for Charcot Marie Tooth Disease Type IIA and Hypertrophic Cardiomyopathy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Cardiac Hypertrophy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GRK5 for Type 2 Diabetes and Cardiac Hypertrophy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block TRPC6 for Diabetic Nephropathy, Hypertrophy Cardiomyopathy and Kidney Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypertrophic Cardiomyopathy – Dormant Projects

Hypertrophic Cardiomyopathy – Product Development Milestones

Featured News & Press Releases

Jun 26, 2018: MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

May 21, 2018: MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

May 10, 2018: MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Apr 02, 2018: MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients

Mar 08, 2018: MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Nov 15, 2017: Preclinical Studies with MyoKardias Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance

Nov 13, 2017: MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor

Nov 02, 2017: MyoKardia Provides Update on Mavacamten

Nov 01, 2017: MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions

Sep 18, 2017: MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting

Aug 07, 2017: MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Nov 11, 2016: MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Nov 02, 2016: MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Sep 21, 2016: MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day

Jul 14, 2016: SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hypertrophic Cardiomyopathy – Pipeline by C&C BioPharma LLC, H2 2018

Hypertrophic Cardiomyopathy – Pipeline by Lead Discovery Center GmbH, H2 2018

Hypertrophic Cardiomyopathy – Pipeline by MyoKardia Inc, H2 2018

Hypertrophic Cardiomyopathy – Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports